Terminated PHASE1/PHASE2 INTERVENTIONAL 7-arm NCT02457910

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer

Sponsor: Conquer Cancer Foundation

Conditions Estrogen Receptor Negative Estrogen Receptor Positive HER2/Neu Negative Progesterone Receptor Negative Progesterone Receptor Positive Stage IV Breast Cancer Triple-Negative Breast Carcinoma

Interventions Biomarker Analysis Enzalutamide Pharmacological Study Taselisib

Updated 14 times since 2017 Last updated: Aug 18, 2022 Started: Jun 30, 2015 Primary completion: Dec 31, 2018 Completion: Aug 8, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Interim analysis - toxicity

Other Estrogen Receptor Negative trials with similar outcome

NCT01319539 · Phase PHASE2 · Jul 2013

Browse all Estrogen Receptor Negative trials

A PHASE1/PHASE2 clinical study on Estrogen Receptor Negative and Estrogen Receptor Positive, this trial is terminated or withdrawn. The trial is conducted by Conquer Cancer Foundation and has accumulated 14 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

14 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Sep 2022 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2

Status: Active Not Recruiting → Terminated
Mar 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2

▶ Show 9 earlier versions

Mar 2021 — Mar 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2021 — Mar 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2
Sep 2019 — Jun 2020 [monthly]

Active Not Recruiting PHASE1_PHASE2
Aug 2018 — Sep 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Suspended → Active Not Recruiting
Jun 2018 — Aug 2018 [monthly]

Suspended PHASE1_PHASE2

Status: Recruiting → Suspended
Aug 2017 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

Status: Suspended → Recruiting
Feb 2017 — Aug 2017 [monthly]

Suspended PHASE1_PHASE2

Status: Recruiting → Suspended
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Conquer Cancer Foundation
Genentech, Inc.
National Cancer Institute (NCI)
Translational Breast Cancer Research Consortium
Vanderbilt-Ingram Cancer Center

Data source: Vanderbilt-Ingram Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Birmingham, United States , Boston, United States , Chapel Hill, United States , Chicago, United States , Houston, United States , Indianapolis, United States , Nashville, United States , Pittsburgh, United States and 2 more locations